FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3214620162> ?p ?o ?g. }

• W3214620162 endingPage "102996" @default.
• W3214620162 startingPage "102996" @default.
• W3214620162 abstract "Transverse myelitis (TM) is a rare but severe systemic lupus erythematosus (SLE) manifestation. To date, the prognostic factors for SLE-associated TM have been far less well-studied. There are also controversial data on the association of antiphospholipid antibodies (aPLs), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score, longitudinal extensive transverse myelitis (LETM), and decreased complement levels with the outcome of TM. We aimed to review the potential prognostic factors and integrate relapse rates of observational studies for SLE-associated TM.To review the prognosis for SLE-associated TM, relevant articles published up to July 30, 2021, were comprehensively and systematically identified from PubMed, EMBASE and Web of Science databases. Five studies encompassing 283 patients with SLE-related TM were included in this meta-analysis; raw data were obtained from three studies.The risk factors for unfavorable neurological outcome included demographic features, clinical characteristics, laboratory data, among which a grade of A, B or C on the American Spinal Injury Association Impairment Scale (AIS) at the onset of TM was associated with poor prognosis (OR: 56.05, 95% CI: 6.29-499.25, P < 0.001). The presence of hypoglycorrhachia was also correlated with a worse prognosis (OR: 10.78, 95% CI: 3.74-31.07, P < 0.001). No noticeable correlation was revealed between a poor outcome and positive aPLs and different aPLs profiles (anticardiolipin antibody [aCL], anti-β2-glycoprotein I (anti-β2GPI], lupus anticoagulant [LA]). The pooled 1-, 3- and 5-year relapse rates were 22% (95% CI: 0.13-0.31), 34% (95% CI: 0.22-0.47) and 36% (95% CI: 0.14-0.58), respectively. No significant publication bias was found.A grade of A, B, or C on the AIS at initial TM and the presence of hypoglycorrhachia were found to be related to a worse prognosis in patients with SLE-associated TM. Notably, aPLs and different aPLs profiles may not suggest poor neurological outcome. The long-term relapse rate of patients with SLE-associated TM was relatively high. We recommend that treatment be stratified based on the initial severity of myelitis. For patients with severe myelitis, early intensive therapy may be initiated as soon as possible." @default.
• W3214620162 created "2021-11-22" @default.
• W3214620162 creator A5010215768 @default.
• W3214620162 creator A5042246197 @default.
• W3214620162 creator A5046149293 @default.
• W3214620162 creator A5046225712 @default.
• W3214620162 creator A5055585688 @default.
• W3214620162 creator A5059300419 @default.
• W3214620162 creator A5066716873 @default.
• W3214620162 creator A5070098915 @default.
• W3214620162 creator A5073523669 @default.
• W3214620162 creator A5087424125 @default.
• W3214620162 date "2022-02-01" @default.
• W3214620162 modified "2023-09-23" @default.
• W3214620162 title "Relapse rates and risk factors for unfavorable neurological prognosis of transverse myelitis in systemic lupus erythematosus: A systematic review and meta-analysis" @default.
• W3214620162 cites W1944753949 @default.
• W3214620162 cites W1947741202 @default.
• W3214620162 cites W1988770489 @default.
• W3214620162 cites W1989979656 @default.
• W3214620162 cites W2004248757 @default.
• W3214620162 cites W2022700178 @default.
• W3214620162 cites W2027615190 @default.
• W3214620162 cites W2070527591 @default.
• W3214620162 cites W2072705150 @default.
• W3214620162 cites W2079999658 @default.
• W3214620162 cites W2088279379 @default.
• W3214620162 cites W2088343102 @default.
• W3214620162 cites W2091280859 @default.
• W3214620162 cites W2094697006 @default.
• W3214620162 cites W2095434093 @default.
• W3214620162 cites W2114638396 @default.
• W3214620162 cites W2115805053 @default.
• W3214620162 cites W2119646998 @default.
• W3214620162 cites W2129671297 @default.
• W3214620162 cites W2153506990 @default.
• W3214620162 cites W2154372819 @default.
• W3214620162 cites W2159860161 @default.
• W3214620162 cites W2161374186 @default.
• W3214620162 cites W2482594565 @default.
• W3214620162 cites W2561536790 @default.
• W3214620162 cites W2725839626 @default.
• W3214620162 cites W2764089668 @default.
• W3214620162 cites W2782380769 @default.
• W3214620162 cites W2792032374 @default.
• W3214620162 cites W2907122372 @default.
• W3214620162 cites W2927871970 @default.
• W3214620162 cites W2956651315 @default.
• W3214620162 cites W3130113466 @default.
• W3214620162 cites W4211013545 @default.
• W3214620162 cites W4211180083 @default.
• W3214620162 cites W4255896580 @default.
• W3214620162 doi "https://doi.org/10.1016/j.autrev.2021.102996" @default.
• W3214620162 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34798313" @default.
• W3214620162 hasPublicationYear "2022" @default.
• W3214620162 type Work @default.
• W3214620162 sameAs 3214620162 @default.
• W3214620162 citedByCount "1" @default.
• W3214620162 countsByYear W32146201622023 @default.
• W3214620162 crossrefType "journal-article" @default.
• W3214620162 hasAuthorship W3214620162A5010215768 @default.
• W3214620162 hasAuthorship W3214620162A5042246197 @default.
• W3214620162 hasAuthorship W3214620162A5046149293 @default.
• W3214620162 hasAuthorship W3214620162A5046225712 @default.
• W3214620162 hasAuthorship W3214620162A5055585688 @default.
• W3214620162 hasAuthorship W3214620162A5059300419 @default.
• W3214620162 hasAuthorship W3214620162A5066716873 @default.
• W3214620162 hasAuthorship W3214620162A5070098915 @default.
• W3214620162 hasAuthorship W3214620162A5073523669 @default.
• W3214620162 hasAuthorship W3214620162A5087424125 @default.
• W3214620162 hasConcept C126322002 @default.
• W3214620162 hasConcept C203014093 @default.
• W3214620162 hasConcept C2776874634 @default.
• W3214620162 hasConcept C2776912625 @default.
• W3214620162 hasConcept C2777185649 @default.
• W3214620162 hasConcept C2779134260 @default.
• W3214620162 hasConcept C2780022809 @default.
• W3214620162 hasConcept C2780640218 @default.
• W3214620162 hasConcept C2780868729 @default.
• W3214620162 hasConcept C71924100 @default.
• W3214620162 hasConcept C90924648 @default.
• W3214620162 hasConceptScore W3214620162C126322002 @default.
• W3214620162 hasConceptScore W3214620162C203014093 @default.
• W3214620162 hasConceptScore W3214620162C2776874634 @default.
• W3214620162 hasConceptScore W3214620162C2776912625 @default.
• W3214620162 hasConceptScore W3214620162C2777185649 @default.
• W3214620162 hasConceptScore W3214620162C2779134260 @default.
• W3214620162 hasConceptScore W3214620162C2780022809 @default.
• W3214620162 hasConceptScore W3214620162C2780640218 @default.
• W3214620162 hasConceptScore W3214620162C2780868729 @default.
• W3214620162 hasConceptScore W3214620162C71924100 @default.
• W3214620162 hasConceptScore W3214620162C90924648 @default.
• W3214620162 hasIssue "2" @default.
• W3214620162 hasLocation W32146201621 @default.
• W3214620162 hasLocation W32146201622 @default.
• W3214620162 hasOpenAccess W3214620162 @default.
• W3214620162 hasPrimaryLocation W32146201621 @default.
• W3214620162 hasRelatedWork W1833690364 @default.
• W3214620162 hasRelatedWork W1947741202 @default.

• next